These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22098470)

  • 1. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma.
    Chen W; Shen X; Xia X; Xu G; Ma T; Bai X; Liang T
    Liver Int; 2012 Jan; 32(1):70-7. PubMed ID: 22098470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells.
    Hu QD; Chen W; Yan TL; Ma T; Chen CL; Liang C; Zhang Q; Xia XF; Liu H; Zhi X; Zheng XX; Bai XL; Yu XZ; Liang TB
    Cancer Lett; 2012 Dec; 325(2):207-13. PubMed ID: 22781398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
    Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.
    Lin L; Amin R; Gallicano GI; Glasgow E; Jogunoori W; Jessup JM; Zasloff M; Marshall JL; Shetty K; Johnson L; Mishra L; He AR
    Oncogene; 2009 Feb; 28(7):961-72. PubMed ID: 19137011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
    Chang AY; Wang M
    Anticancer Drugs; 2013 Mar; 24(3):251-9. PubMed ID: 23187461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma.
    Geng J; Li X; Lang X; Qiao C; Hu M; Yang J; Feng J; Lv M
    Technol Cancer Res Treat; 2014 Aug; 13(4):377-85. PubMed ID: 24325131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
    Fuchs BC; Fujii T; Dorfman JD; Goodwin JM; Zhu AX; Lanuti M; Tanabe KK
    Cancer Res; 2008 Apr; 68(7):2391-9. PubMed ID: 18381447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
    Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
    Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
    Chen KF; Su JC; Liu CY; Huang JW; Chen KC; Chen WL; Tai WT; Shiau CW
    Cancer Lett; 2012 Aug; 321(1):27-35. PubMed ID: 22465052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines.
    Wang X; Goldstein D; Crowe PJ; Yang JL
    Int J Oncol; 2018 Jun; 52(6):2143-2154. PubMed ID: 29620166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
    Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS
    J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.
    Bonner JA; Yang ES; Trummell HQ; Nowsheen S; Willey CD; Raisch KP
    Radiother Oncol; 2011 Jun; 99(3):339-43. PubMed ID: 21704410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-based targeting of CD24 enhances antitumor effect of cetuximab via attenuating phosphorylation of Src/STAT3.
    Chen Z; Wang T; Tu X; Xie W; He H; Wang M; Zhang J
    Biomed Pharmacother; 2017 Jun; 90():427-436. PubMed ID: 28391164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer.
    Huether A; Höpfner M; Baradari V; Schuppan D; Scherübl H
    Biochem Pharmacol; 2005 Nov; 70(11):1568-78. PubMed ID: 16226226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
    Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
    Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.
    Zuo M; Li C; Lin J; Javle M
    Oncotarget; 2015 May; 6(13):10940-9. PubMed ID: 25883212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
    Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
    J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of suppressors of cytokine signaling 3 promotes aggressiveness in hepatocellular carcinoma.
    Wu WY; Kim H; Zhang CL; Meng XL; Wu ZS
    J Invest Surg; 2014 Aug; 27(4):197-204. PubMed ID: 24476004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.